SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-283317
Filing Date
2020-11-02
Accepted
2020-11-02 07:08:02
Documents
14
Period of Report
2020-11-02
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d16906d8k.htm   iXBRL 8-K 25373
2 EX-99.1 d16906dex991.htm EX-99.1 596684
6 GRAPHIC g16906horizon.jpg GRAPHIC 3764
  Complete submission text file 0001193125-20-283317.txt   805394

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA hznp-20201102.xsd EX-101.SCH 3085
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE hznp-20201102_lab.xml EX-101.LAB 18840
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE hznp-20201102_pre.xml EX-101.PRE 11849
7 EXTRACTED XBRL INSTANCE DOCUMENT d16906d8k_htm.xml XML 3657
Mailing Address CONNAUGHT HOUSE, 1ST FLOOR 1 BURLINGTON ROAD DUBLIN L2 4
Business Address CONNAUGHT HOUSE, 1ST FLOOR 1 BURLINGTON ROAD DUBLIN L2 4 011-353-1-772-2100
Horizon Therapeutics Public Ltd Co (Filer) CIK: 0001492426 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35238 | Film No.: 201278957
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences